Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8941 results

  1. Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block (TA88)

    Evidence-based recommendations on using dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome or atrioventricular block.

    Technology appraisal guidance
    Last updated
    1 November 2014
    View recommendations

    Sections for TA88

  2. Naloxegol for treating opioid‑induced constipation (TA345)

    Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA345

  3. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

    Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA347

  4. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA412

  5. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

    Technology appraisal guidance
    Published
    7 August 2024
    View recommendations

    Sections for TA993

  6. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.

    Technology appraisal guidance
    Published
    29 August 2024
    View recommendations

    Sections for TA997

  7. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. CT hepatic arteriography for patients undergoing percutaneous ablation of primary or secondary liver tumours

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  9. Wireless breast lesion localization using Savi Scout seed

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  10. AHEAD implants for external ear prosthesis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. Insertion of Stoma Preservation Device

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Botulinum Toxin injection prior to Abdominal wall reconstruction

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation